Valerio Therapeutics stock
ALVIO.PAPARValerio Therapeutics S.A., HealthcareISIN FR0010095596
40Score 40 out of 100, Weak
Price and trend
76 / 100
Price history
+211% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 60).
The price is 48% below its 52-week high. Largest decline in 3 years: 87% (August 2023 to February 2025).
Chart figures for advanced users
- SMA 50$0.57
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$0.41
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)60
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$0.12
- The lowest closing price of the last twelve months.
- Resistance$0.98
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Valerio Therapeutics S.A. belongs to the Biotechnology industry (France) and, with a market value of $296.19M, is number 293 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.86M (up 43.5% year on year) and a loss of $5.45M.
- MEQIRI Score 40 out of 100 (Weak): rank 551 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $0.19, with the price 172% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- DilutionShare count up 111% since 2020.Capital allocation 18
- Above fair valuePrice 172% above the fair value of $0.19.Valuation 23
- Volatile share priceVolatility 122% a year over the last 12 months.Stability 8
Its standout strengths are momentum and technical analysis, while fundamentals and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price up very strongly over the past year
What lowers it
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $0.13 and expensive above $0.39 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.9%. At 9.9% the fair value would be $0.17, at 7.9% it would be $0.23.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 43.5% on the prior year. Revenue has grown solidly since 2006, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 67%, operating −21%, net −190%. Last 12 months: net −100%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 3 Mar 2027in 111 days
- Last reported
- 2 Sep 2026EPS reported −$0.02
What happened at Valerio Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 40
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Vicore Pharma HoldingVICO.ST $318.18M38
- Kyverna TherapeuticsKYTX $316.64M28
- EvommuneEVMN $312.84M33
- Cabaletta BioCABA $312.79M28
- Allogene TherapeuticsALLO $311.85M27
- Nautilus BiotechnolgyNAUT $308.24M40
- FormyconFYB.DE $294.18M31
- Heidelberg PharmaHPHA.DE $110.36M28
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Overvalued since 10 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.